3-weekly daratumumab-lenalidomide/pomalidomide-dexamethasone is highly effective in relapsed and refractory multiple myeloma. - Chim, Chor Sang; Kumar, Shaji; Wong, Vincent Kai Chung; Ngai, Cheong; Kwong, Yok Lam (Hematology, 2021)